<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750202</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-MISP-53183</org_study_id>
    <nct_id>NCT02750202</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts</brief_title>
  <acronym>TheraVACCS</acronym>
  <official_title>Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pretoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pretoria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in
      South Africa. Medical and destructive therapy for small warts is generally very effective,
      however unique problems posed by large or extensive genital warts are not so easily solved
      and treatment of affected patients remains very challenging. Recurrences are common
      especially among immune-compromised women. This study will test whether giving the
      quadrivalent human papilloma virus (HPV) vaccine to women with extensive genital warts prior
      to surgical treatment will improve outcomes. Investigators hypothesize that pre-treatment
      with HPV vaccine can play a role in the control of both malignant and benign HPV disease in
      women with and without HIV infection through stimulation of the antibody response. In
      addition, HPV types and other associated diseases will be studied in women receiving HPV
      vaccine and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient selection:

      Female patients referred or presenting with genital warts at each site will be eligible and
      evaluated against the inclusion and exclusion criteria.

      Women who are clinically or severely immune-compromised will not be included into the study,
      but both HIV negative and HIV infected women will be included. Seventy-five women with large
      or recurrent genital warts will be recruited for this study from 2 sites in South Africa.

      Recruitment:

      Women with genital warts will be evaluated for inclusion into the study. Those who fit the
      inclusion criteria and are without any of the exclusion criteria will be fully informed and
      invited to participate. The first target will be to recruit the first seventy-five
      consecutive eligible patients who have signed written consent; recruitment for the study will
      be done for at least 24 months.

      First clinical visit:

        -  Evaluation genital lesions:

      On study entry tumour size and position will be documented graphically and photographically
      and viral typing from the vulva wart and cervix will be done using Roche Linear Array test.

        -  Evaluation immune status:

      HIV status and CD 4/CD 8 count will be recorded and tested and the serum will be collected
      for antibody testing. Cervical disease of clinical significance will be excluded or treatment
      offered if relevant.

        -  Randomization:

      Patients will be randomized to receive either quadrivalent HPV or Hepatitis B vaccine.

        -  Vaccination:

      The participants assigned to the test group will be administered quadrivalent HPV vaccine in
      three doses as recommended by the manufacturer. Participants assigned to the control group
      will receive Hepatitis B vaccine in three doses as recommended by the manufacturer.

      Follow-up clinical visits: week 8, week 16 and week 24:

        -  Evaluation genital lesions:

      Three follow up visits will be scheduled two months apart at which time the lesion size will
      be recorded.

        -  Evaluation immune status:

      After month 6 or the third visit, the serum will again be collected for antibody level
      testing.

        -  Treatment decision:

      According to the clinical response as measured at month six and onwards, locally destructive
      or surgical treatment will be allowed according to the preference of the clinician and as
      determined by clinical factors.

      Follow up after treatment:

        -  Follow up will be done at six monthly intervals.

        -  Evaluation genital lesions:

      At these visits lesion size will be determined and documented. HPV typing on the cervical and
      vulval lesions will be repeated at least once.

        -  Further treatment of warts:

      If needed, repeat surgery and/or local destruction will be allowed and documented. These will
      be around week 48 and week 72, or study exit

      Study exit:

        -  Participants will exit the study in week 72.

        -  In the absence of harm as determined at interim analysis or suggested by participant
           disease history, researchers will be unblinded for participant status at study exit and
           alternative vaccines will be offered to each of these women.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the maximum size of the genital wart lesion over the trial period (as measured in mm)</measure>
    <time_frame>Baseline, week 8, 16, 24, 36, 48, 60, 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who acquire measurable levels of HPV type specific antibodies during the first 18 months of the trail as measured using a competitive Luminex immuno-assay (cLIA; reported in milli-Merck Units [mMU]/ml)</measure>
    <time_frame>Week 36+</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who change from HPV 6 DNA positive in warts to negative at week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who change from HPV 11 DNA positive in warts to negative at week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who change from HPV 16 DNA positive at baseline to negative at week 60</measure>
    <time_frame>Baseline, week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who change from HPV 18 DNA positive at baseline to negative at week 60</measure>
    <time_frame>Baseline, week 60</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants who change from HIV negative at baseline to positive at week 48</measure>
    <time_frame>Baseline, week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants who require surgical treatment of warts at any of the clinical assessments during the trial, as judged by the attending clinician.</measure>
    <time_frame>Week 24, 72</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants who require surgical treatment of cervical disease at any of the clinical assessments during the trial, as judged by the attending clinician.</measure>
    <time_frame>Week 24, 72</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>Quadrivalent HPV vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of 4 HPV vaccine is given at registered intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B vaccine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent HPV vaccine</intervention_name>
    <description>Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.</description>
    <arm_group_label>Quadrivalent HPV vaccine</arm_group_label>
    <other_name>Gardasil</other_name>
    <other_name>4 HPV vaccine</other_name>
    <other_name>q HPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B vaccine</intervention_name>
    <description>Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.</description>
    <arm_group_label>Hepatitis B vaccine</arm_group_label>
    <other_name>Hep B vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient &gt; 16 years

          -  Presence of vulvo vaginal genital warts: largest tumour diameter &gt; 3 cm OR Tumour on
             labia minora and labia majora OR bilateral &gt; 1 cm each side OR Tumour in vagina/cervix
             as well as on vulva &gt; 1 cm lesion each

          -  HIV negative or HIV infected and CD4 â‰¥ 300 cells/mm3 OR viral load controlled OR anti
             retro-viral (ARV) compliant &gt; 6 months

        Exclusion Criteria:

          -  Pregnant of planned pregnancy within 6 months

          -  Not able to comprehend study method or not able to attend all study visits

          -  Previous HPV vaccination

          -  Active known opportunistic infection or malignancy including Pneumocystis pneumonia
             (PCP),Pulmonary tuberculosis (PTB), oesophageal Candida or Kaposi sarcoma or lymphoma

          -  Known allergy to vaccines or content of vaccine

          -  Previous radiation for genital warts
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greta G Dreyer, MMed(O&amp;G)PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pretoria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greta G Dreyer, MMed(O&amp;G)PhD</last_name>
    <phone>+27 12 354 3900</phone>
    <email>Greta.Dreyer@up.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathy Visser, BSc(Hons)MSc</last_name>
    <phone>+27 82 403 0691</phone>
    <email>visser.cathy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Visser, MSc</last_name>
      <phone>+27 12 354 3900</phone>
      <email>visser.cathy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leon C Snyman, MMedO&amp;G;FCOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederick H van der Merwe, MMedO&amp;G,FCOG</last_name>
      <phone>+27 21 938 9209</phone>
      <email>haynes@sun.ac.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pretoria</investigator_affiliation>
    <investigator_full_name>Professor Greta Dreyer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Genital warts</keyword>
  <keyword>HPV types</keyword>
  <keyword>HPV vaccine</keyword>
  <keyword>Cervical cytology</keyword>
  <keyword>Therapeutic vaccine</keyword>
  <keyword>Quadrivalent HPV vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

